GLP-1 drugs were also associated with a slight increase in risk for kidney cancer. The increase was not statistically ...

GLP-1s aren't FDA-approved to treat rheumatoid arthritis, but many people notice improvement in their inflammation with the ...

The retired tennis pro explained that she’s trying to combat the stigma associated with weight loss drugs after losing 31 ...

Serena Williams' suggestion that injectable weight loss drugs could have helped her in tennis is part of an ongoing discussion in the sports world.

Serena Williams revealed how she turned her health around with the help of a GLP-1 medication after she struggled to lose ...

A study has found that adults with obesity taking GLP-1 receptor agonists may face significantly lower risk of developing certain cancers. The cohort study was led by researchers from the Indiana ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...